Cisplatin, 5-fluorouracil, and leucovorin in the therapy of adenocarcinomas of the pancreas

D. V. Jones, S. M. Sugarman, Avi Markowitz, B. Levin, J. L. Abbruzzese, D. B. Evans, C. Charnsangavej, R. Smith, Y. Z. Patt

    Research output: Contribution to journalArticle

    Abstract

    Pancreatic cancer is resistant to most chemotherapeutic regimens. Based upon evidence of synergy between 5-fluorouracil (5-FU) and cisplatin (CDDP), and of enhanced 5-FU activity in the presence of leucovorin in other neoplasms, a phase II study of CDDP, 5-FU, and leucovorin was conducted to determine the efficacy of this regimen in patients with unresectable adenocarcinomas of the pancreas. Nineteen patients were enrolled, and all were evaluable for toxicity and response. One complete and two partial responses were observed (15.8%). Adverse effects were reversible and tolerable. This regimen has limited activity against pancreatic cancer, and cannot be recommended as standard therapy in this disease.

    Original languageEnglish (US)
    Pages (from-to)1121-1123
    Number of pages3
    JournalOncology Reports
    Volume2
    Issue number6
    StatePublished - 1995

    Fingerprint

    Leucovorin
    Fluorouracil
    Cisplatin
    Pancreas
    Adenocarcinoma
    Pancreatic Neoplasms
    Therapeutics
    Neoplasms

    Keywords

    • 5-fluorouracil
    • Chemotherapy
    • Cisplatin
    • Drug synergy
    • Leucovorin
    • Pancreatic cancer

    ASJC Scopus subject areas

    • Cancer Research
    • Oncology

    Cite this

    Jones, D. V., Sugarman, S. M., Markowitz, A., Levin, B., Abbruzzese, J. L., Evans, D. B., ... Patt, Y. Z. (1995). Cisplatin, 5-fluorouracil, and leucovorin in the therapy of adenocarcinomas of the pancreas. Oncology Reports, 2(6), 1121-1123.

    Cisplatin, 5-fluorouracil, and leucovorin in the therapy of adenocarcinomas of the pancreas. / Jones, D. V.; Sugarman, S. M.; Markowitz, Avi; Levin, B.; Abbruzzese, J. L.; Evans, D. B.; Charnsangavej, C.; Smith, R.; Patt, Y. Z.

    In: Oncology Reports, Vol. 2, No. 6, 1995, p. 1121-1123.

    Research output: Contribution to journalArticle

    Jones, DV, Sugarman, SM, Markowitz, A, Levin, B, Abbruzzese, JL, Evans, DB, Charnsangavej, C, Smith, R & Patt, YZ 1995, 'Cisplatin, 5-fluorouracil, and leucovorin in the therapy of adenocarcinomas of the pancreas', Oncology Reports, vol. 2, no. 6, pp. 1121-1123.
    Jones DV, Sugarman SM, Markowitz A, Levin B, Abbruzzese JL, Evans DB et al. Cisplatin, 5-fluorouracil, and leucovorin in the therapy of adenocarcinomas of the pancreas. Oncology Reports. 1995;2(6):1121-1123.
    Jones, D. V. ; Sugarman, S. M. ; Markowitz, Avi ; Levin, B. ; Abbruzzese, J. L. ; Evans, D. B. ; Charnsangavej, C. ; Smith, R. ; Patt, Y. Z. / Cisplatin, 5-fluorouracil, and leucovorin in the therapy of adenocarcinomas of the pancreas. In: Oncology Reports. 1995 ; Vol. 2, No. 6. pp. 1121-1123.
    @article{01228e496bea4f8a8273bc5d02e8ad25,
    title = "Cisplatin, 5-fluorouracil, and leucovorin in the therapy of adenocarcinomas of the pancreas",
    abstract = "Pancreatic cancer is resistant to most chemotherapeutic regimens. Based upon evidence of synergy between 5-fluorouracil (5-FU) and cisplatin (CDDP), and of enhanced 5-FU activity in the presence of leucovorin in other neoplasms, a phase II study of CDDP, 5-FU, and leucovorin was conducted to determine the efficacy of this regimen in patients with unresectable adenocarcinomas of the pancreas. Nineteen patients were enrolled, and all were evaluable for toxicity and response. One complete and two partial responses were observed (15.8{\%}). Adverse effects were reversible and tolerable. This regimen has limited activity against pancreatic cancer, and cannot be recommended as standard therapy in this disease.",
    keywords = "5-fluorouracil, Chemotherapy, Cisplatin, Drug synergy, Leucovorin, Pancreatic cancer",
    author = "Jones, {D. V.} and Sugarman, {S. M.} and Avi Markowitz and B. Levin and Abbruzzese, {J. L.} and Evans, {D. B.} and C. Charnsangavej and R. Smith and Patt, {Y. Z.}",
    year = "1995",
    language = "English (US)",
    volume = "2",
    pages = "1121--1123",
    journal = "Oncology Reports",
    issn = "1021-335X",
    publisher = "Spandidos Publications",
    number = "6",

    }

    TY - JOUR

    T1 - Cisplatin, 5-fluorouracil, and leucovorin in the therapy of adenocarcinomas of the pancreas

    AU - Jones, D. V.

    AU - Sugarman, S. M.

    AU - Markowitz, Avi

    AU - Levin, B.

    AU - Abbruzzese, J. L.

    AU - Evans, D. B.

    AU - Charnsangavej, C.

    AU - Smith, R.

    AU - Patt, Y. Z.

    PY - 1995

    Y1 - 1995

    N2 - Pancreatic cancer is resistant to most chemotherapeutic regimens. Based upon evidence of synergy between 5-fluorouracil (5-FU) and cisplatin (CDDP), and of enhanced 5-FU activity in the presence of leucovorin in other neoplasms, a phase II study of CDDP, 5-FU, and leucovorin was conducted to determine the efficacy of this regimen in patients with unresectable adenocarcinomas of the pancreas. Nineteen patients were enrolled, and all were evaluable for toxicity and response. One complete and two partial responses were observed (15.8%). Adverse effects were reversible and tolerable. This regimen has limited activity against pancreatic cancer, and cannot be recommended as standard therapy in this disease.

    AB - Pancreatic cancer is resistant to most chemotherapeutic regimens. Based upon evidence of synergy between 5-fluorouracil (5-FU) and cisplatin (CDDP), and of enhanced 5-FU activity in the presence of leucovorin in other neoplasms, a phase II study of CDDP, 5-FU, and leucovorin was conducted to determine the efficacy of this regimen in patients with unresectable adenocarcinomas of the pancreas. Nineteen patients were enrolled, and all were evaluable for toxicity and response. One complete and two partial responses were observed (15.8%). Adverse effects were reversible and tolerable. This regimen has limited activity against pancreatic cancer, and cannot be recommended as standard therapy in this disease.

    KW - 5-fluorouracil

    KW - Chemotherapy

    KW - Cisplatin

    KW - Drug synergy

    KW - Leucovorin

    KW - Pancreatic cancer

    UR - http://www.scopus.com/inward/record.url?scp=0028844160&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0028844160&partnerID=8YFLogxK

    M3 - Article

    AN - SCOPUS:0028844160

    VL - 2

    SP - 1121

    EP - 1123

    JO - Oncology Reports

    JF - Oncology Reports

    SN - 1021-335X

    IS - 6

    ER -